SEARCH

SEARCH BY CITATION

In the AASLD Practice Guideline published in the April issue of HEPATOLOGY 2004;39:1147–1171, “Diagnosis, management, and treatment of hepatitis C” the following corrections should be noted:

In Table 4, the upper dynamic range limit of the quantitative assay is incorrectly expressed in the third row. The table is correct as listed below:

Table 4. Assays for Quantitation of HCV RNA in Serum
Assay*1 IU/L ConversionTechniqueDynamic Range (IU/L)
  • NOTE. Table adapted from Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. HEPATOLOGY 2002;36(suppl 1):565–573.

  • Abbreviation: rtPCR, reverse transcriptase polymerase chain reaction.

  • *

    Amplicor HCV Monitor version 2.0 and Cobas Amplicor Monitor HCV version 2.0 (Roche Molecular Systems, Branchburg, NJ); VERSANT® HCV RNA version 3.0 (Bayer Diagnostics, Tarrytown, NY); LCx HCV RNA (Abbott Diagnostics, Chicago, IL); SuperQuant (National Genetics Institute, Los Angeles, CA).

Amplicor HCV Monitor version # 2.00.9 copies/mLManual competitive rtPCR600–500,000
Cobas Amplicor Monitor HCV Version # 2.02.7 copies/mLSemi-automated competitive rtPCR600–500,000
VERSANT® HCV RNA version # 3.0 Quantitative Assay5.2 copies/mLSemi-automated “branched DNA” assay615–7,700,000
LCx HCV RNA Quantitative Assay3.8 copies/mLSemi-automated competitive rtPCR25–2,630,000
SuperQuant3.4 copies/mLSemi-automated competitive rtPCR30–1,470,000

On page 1149 of the article under the heading Qualitative Assays, the paragraph should appear as follows:

HCV RNA can be detected in blood using amplification techniques such as polymerase chain reaction (PCR) or transcription-mediated amplification (TMA).28 The Food and Drug Administration (FDA) has approved 2 PCR-based tests for qualitative detection of HCV RNA; (1) Amplicor Hepatitis C Virus Test, version 2.0, and (2) Cobas Amplicor Hepatitis C Virus Test, version 2.0 (Roche Molecular Systems, Branchburg, NJ), which have limits of detection of approximately 50 IU/mL. A third approved test is the VERSANT® HCV RNA Qualitative Assay (Bayer Diagnostics, Tarrytown, NY) which employs the TMA technology and has a sensitivity limit of 9.6 IU/mL. Other commercially available non-approved assays are used by some diagnostic laboratories.